Overview

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Phase:
Phase 2
Details
Lead Sponsor:
MorphoSys AG
Treatments:
Felzartamab